PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Single dose of PF-07104091 as Tablet Formulation A (Treatment A)
Drug: Single dose of PF-07104091 as Tablet Formulation B (Treatment B)
Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment C)
Drug: Single dose of PF-07104091 as Tablet Formulation D (Treatment D)
Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment E)

First Posted Date: 2022-06-24

Last Posted Date: 2024-04-08

Lead Sponsor: Pfizer

Target Recruit Count: 30

Registration Number: NCT05431153

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy

Phase 2

Active, not recruiting

Conditions: Muscular Dystrophy, Duchenne

Interventions: Genetic: PF-06939926

First Posted Date: 2022-06-23

Last Posted Date: 2025-05-15

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT05429372

Locations: 🇺🇸
UF Health Shands Hospital, Gainesville, Florida, United States
🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇦🇺
The Children's Hospital at Westmead, Westmead, New South Wales, Australia

and more 9 locations

A Study to Learn How the Study Medicine Called PF-07275315 Works in Healthy People

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Placebo
Drug: PF-07275315

First Posted Date: 2022-06-09

Last Posted Date: 2025-05-25

Lead Sponsor: Pfizer

Target Recruit Count: 65

Registration Number: NCT05411588

Locations: 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

and more 1 locations

A Study to Learn About Sickle Cell Disease In Adult Patients

Completed

Conditions: Sickle Cell Disease

Interventions: Other: Electronic Diary

First Posted Date: 2022-06-07

Last Posted Date: 2024-07-16

Lead Sponsor: Pfizer

Target Recruit Count: 98

Registration Number: NCT05407805

Locations: 🇺🇸
Mid-Atlantic Permanente Medical Group Largo Medical Center, Upper Marlboro, Maryland, United States
🇺🇸
Sanguine Biosciences, Inc., Waltham, Massachusetts, United States
🇺🇸
Cohen Children's Medical Center, New Hyde Park, New York, United States

and more 1 locations

Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13

Phase 3

Completed

Conditions: Pneumococcal Disease

Interventions: Biological: 13-valent pneumococcal conjugate vaccine
Biological: 20-valent pneumococcal conjugate vaccine

First Posted Date: 2022-06-07

Last Posted Date: 2023-11-03

Lead Sponsor: Pfizer

Target Recruit Count: 356

Registration Number: NCT05408429

Locations: 🇭🇺
Lurko-Med Kft Hazi Gyermekorvosi Rendelo, Budapest, Hungary
🇵🇱
IN-VIVO Bydgoszcz, Bydgoszcz, Poland
🇵🇱
Uniwersytecki Szpital Kliniczny im. J. Mikulicza-Radeckiego we Wroclawiu, Wroclaw, Poland

and more 33 locations

Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

Active, not recruiting

Conditions: Breast Cancer

First Posted Date: 2022-06-01

Last Posted Date: 2024-07-15

Lead Sponsor: Pfizer

Target Recruit Count: 688

Registration Number: NCT05399329

Locations: 🇯🇵
Japan Community Health care Organization Kurume General Hospital, Kurume-city, Fukuoka, Japan
🇯🇵
Tohoku University Hospital, Sendai, Miyagi, Japan
🇯🇵
Osaka International Cancer Institute, Osaka-shi, Osaka, Japan

and more 17 locations

Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)

Phase 3

Completed

Conditions: Migraine

Interventions: Drug: Placebo
Drug: Rimegepant

First Posted Date: 2022-06-01

Last Posted Date: 2025-01-08

Lead Sponsor: Pfizer

Target Recruit Count: 496

Registration Number: NCT05399485

Locations: 🇯🇵
Medical Corporation Seikokai Takanoko Hospital, Matsuyama-shi, Ehime, Japan
🇯🇵
Jinnouchi Neurosurgical Clinic, Kasuga-shi, Fukuoka, Japan
🇯🇵
Ikeda Neurosurgical Clinic, Kasuga-shi, Fukuoka, Japan

and more 41 locations

Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)

Phase 3

Completed

Conditions: Migraine

Interventions: Drug: Rimegepant 25 MG
Drug: Rimegepant 75 MG
Drug: Placebo

First Posted Date: 2022-06-01

Last Posted Date: 2025-03-07

Lead Sponsor: Pfizer

Target Recruit Count: 897

Registration Number: NCT05399459

Locations: 🇯🇵
Narikawa Neurological Clinic, Izumi-ku, Miyagi, Japan
🇯🇵
Tokyo Headache Clinic, Shibuya-Ku, Tokyo, Japan
🇯🇵
Fukuuchi Pain Clinic, Shinjuku-ku, Tokyo, Japan

and more 47 locations

An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK

Completed

Conditions: Advanced Renal Cell Carcinoma

Interventions: Drug: avelumab
Drug: axitinib

First Posted Date: 2022-05-27

Last Posted Date: 2023-12-06

Lead Sponsor: Pfizer

Target Recruit Count: 130

Registration Number: NCT05394493

Locations: 🇬🇧
Pfizer Ltd, Sandwich, Kent, United Kingdom

A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis

Recruiting

Conditions: Dermatitis, Atopic

First Posted Date: 2022-05-25

Last Posted Date: 2025-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 1100

Registration Number: NCT05391061

Locations: 🇰🇷
Pfizer Tower, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy